- Prostate cancer is one of the most
common types of cancer in men
- Inherited mutations are tied to
advanced prostate cancer risk
- Screening for mutations in
DNA-repair genes and BRAC1 and BRAC2 genes can benefit men with metastatic
Genetic screening could help men with
prostate cancer find better treatment options. Men with advanced prostate
cancer could benefit from screening for mutations in DNA-repair genes including
the breast cancer genes (BRAC1 and BRAC2). The study published in The
New England Journal of Medicine
was led by researchers at Fred
Hutchinson Cancer Research Center and the University of Washington.
'DNA repair genes'
help maintain the integrity of the genetic code of the cell. If there is a mutation in the DNA repair genes, the DNA is less likely to repaired when there is an aberration in its code thereby increasing the cancer risk of the cell.
‘Genetic screening could help men with prostate cancer find better treatment options. Men with advanced prostate cancer are five times more likely than general population to carry an inherited mutation in their DNA-repair genes and breast cancer genes.’
occurs in the prostate gland of men. Prostate is a small walnut-shaped gland that produces seminal fluid that nourishes and transports sperms after ejaculation. Prostate cancer, when detected early, has a better chance of successful treatment; however most men present late once the cancer has advanced and has metastasized to other organs. When discovered late the prognosis of cancer is poor. The current research addresses this issue to help detect inherited mutations that make a person more prone to metastasis of cancer.
gathered genetic information from 692 men with metastatic prostate cancer
across seven different groups of patients and several institutions including
Fred Hutch and the University of Washington through support from StandUp2Cancer
and the Prostate Cancer Foundation. Using next-generation sequencing assays,
independent screening of mutations in 20 DNA repair genes was conducted.
- 11.8% of men with advanced
(metastatic) prostate cancer, irrespective of age or family history of
prostate cancer have deleterious germline mutations in one of the 20 DNA
- Men with metastatic prostate
cancer are five times likelier than the general population to carry the
- The risk of carrying a BRCA2
mutation is 18 times higher in men with advanced prostate cancer than men
without prostate cancer
Importantly the men used in the study were not chosen because of age
or family history, giving an extra reliability to the results. The screening
done at different laboratories produced the same results across the board,
adding further strength to the study findings.
Medindia interviewed doctors
who published this paper to look at the implication of this important research
that is likely to help patients with advanced prostate cancer.
Here are excerpts from Dr. Colin C. Pritchard
, Associate Professor in the
Department of Laboratory Medicine, and Associate Director of the Genetics and
Solid Tumors Laboratory at the University of Washington School of Medicine the first
author of the study
and Dr. Peter Nelson,
a member of the Human
Biology, Clinical Research and Public Health Sciences divisions at Fred
Hutchinson Cancer Research Center and senior and corresponding author of the
1. Question -
You have recommended germline DNA testing as a part of
standard care for men with metastatic prostate cancer. Your report also said -
in the key results of the study found that 11.8 percent of men with metastatic
prostate cancer, regardless of age or family history of prostate cancer, have
deleterious germline mutations in one of 20 DNA repair genes.
Do you believe that this should be true for all ethnic
population groups that present with such cancer? We do know that blacks have more
aggressive prostate cancer. Do you think that this percentage may be higher in
this ethnic group of people?
Dr. Colin Pritchard - This is a good question. It does seem
likely that there will be differences in mutation rates in different
ethnicities and there are already some prostate genetic markers that have been
described in this context. Although we did not see a significant difference in
mutation rate according to ethnicity in our series, our study was not powered
to detect such differences, so future research will be needed to address this.
Dr. Peter Nelson
added that "It would be useful to replicate our study
specifically in other ethnic and racial groups as our study was comprised
primarily of Caucasian men."
2. Question -
Your report mentions that - Men with such mutations
could benefit from targeted treatment already approved for ovarian cancer
patients with these mutations, such as PARP inhibitors or platinum drugs. Could
you please elaborate on this and also will gene therapy help such metastatic
repair gene mutations, particularly in the subset of DNA repair genes known as
"homologous recombination DNA repair" appear to sensitize cancers to certain
DNA-damaging drugs such as
PARP inhibitors and platinum drugs.
There is a recent study published in the New England Journal of Medicine
that found that the majority of men whose tumors had DNA repair gene mutations
responded to PARP inhibitor therapy, while only a small minority of those
without DNA repair gene mutations responded.
This study and another accumulating evidence have led the FDA in the United States to expedite its review of PARP
inhibitors for use in advanced prostate cancer. It is important to clarify that
DNA repair genes may be inherited, or acquired in tumor, so PARP inhibitors and
platinum therapy is likely to benefit more than just the men with inherited
mutations. We estimate that about 20 to
25% of advanced prostate cancers have these mutations, with about half being
inherited, and the other half being acquired in the tumor.
On gene therapy for prostate cancer, Dr. Peter Nelson added that "Currently,
there is not an effective way to use gene therapy or gene editing to modify the
DNA repair process in tumor cells, so at this time gene therapy in the
conventional sense would not be applicable."
Prostate Cancer Facts
- It is the most common cancer among men after skin cancer
- More than 2 million men in the United States count themselves as prostate cancer survivors
- About 6 cases in 10 are diagnosed in men aged 65 or older.
- 176,450 men in the United States are diagnosed with prostate cancer
- 27,681 men in the United States died from prostate cancer
- Prostate cancer is more aggressive in black population than white population
The Future Treatment
of Prostate Cancer
This research project could
shed light on new cancer risk mutations and find out how a specific mutation
may or may not impact risk of cancer. Further research will validate these
findings and determine the genetic mutations that predispose men to a most
aggressive form of prostate cancer. Once established these will become
guidelines in clinical practice. References:
- Key statistics for prostate cancer - http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics)
- Prostate Cancer - (http://www.cancer.org/cancer/prostatecancer/)
- Prostate cancer statistics - (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer)